PD48-05 INCREASED B4GALT1 EXPRESSION IS ASSOCIATED WITH ADVERSE ONCOLOGIC OUTCOMES IN LOCALIZED CLEAR CELL RENAL CELL CARCINOMA

Huyang Xie,Qiang Fu,Xiaoqun Yang,Jiejie Xu,Dingwei Ye

DOI: https://doi.org/10.1016/j.juro.2016.02.2727

2016-01-01

Abstract:You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy VI1 Apr 2016PD48-05 INCREASED B4GALT1 EXPRESSION IS ASSOCIATED WITH ADVERSE ONCOLOGIC OUTCOMES IN LOCALIZED CLEAR CELL RENAL CELL CARCINOMA Huyang Xie, Qiang Fu, Xiaoqun Yang, Jiejie Xu, and Dingwei Ye Huyang XieHuyang Xie More articles by this author , Qiang FuQiang Fu More articles by this author , Xiaoqun YangXiaoqun Yang More articles by this author , Jiejie XuJiejie Xu More articles by this author , and Dingwei YeDingwei Ye More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2727AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES B4GALT1 is one of seven beta-1,4-galactosyltransferase (beta4GalT) genes, which encode type II membrane-bound glycoproteins that appear to have exclusive specificity for the donor substrate UDP-galactose. According to previous studies aberrant B4GALT1 expression has distinct functions in different tumors. Here, we evaluate the association of B4GALT1 expression with oncologic outcomes in patients with localized clear cell renal cell carcinoma (ccRCC) managed by surgery. METHODS A retrospective analysis of 207 and 231 patients with localized ccRCC undergoing RN or NSS at two academic medical centers respectively between 2005 and 2009 was performed. The first cohort with 207 patients was treated as training set and the other as validation set. Tissue microarrays (TMAs) were created in triplicate from formalin-fixed, paraffin embedded specimens. Immunohistochemistry with a commercially available monoclonal B4GALT1 antibody was performed with the intensity (0 to 3) and percentage (0 of 100) of staining recorded. The association of B4GALT1 expression with standard pathologic features and prognosis were evaluated. RESULTS B4GALT1 expression was significantly associated with tumor T stage (P<0.001 and P<0.001, respectively), Fuhrman grade (P<0.001 and P<0.001, respectively) and necrosis (P=0.021 and P=0.002, respectively) in both training and validation sets. Moreover, high B4GALT1 expression indicated poor overall sruvival (OS) (P<0.001 and P<0.001, respectively) in the two sets. The incorporation of B4GALT1 into T stage and Fuhrman grade would help to refine individual risk stratification. Furthermore, B4GALT1 expression was identified as an independent adverse prognostic factor for survival. A predictive nomogram was generated with identified independent prognositicators to assess patient overall survival at 5 and 10 years. CONCLUSIONS Increased B4GALT1 expression is a potential independent adverse prognostic factor for overall survival in patients with localized ccRCC. Inhibting B4GALT1 pathway might be a promising target of postoperative adjuvant therapy for these ccRCC patients. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e1176-e1177 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Huyang Xie More articles by this author Qiang Fu More articles by this author Xiaoqun Yang More articles by this author Jiejie Xu More articles by this author Dingwei Ye More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...